Description
Description: Xovoltib, containing the active substance afatinib, is a medication commonly prescribed for the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) and metastatic squamous cell carcinoma of the lung. Afatinib is classified as a tyrosine kinase inhibitor, specifically targeting the epidermal growth factor receptor (EGFR) family of proteins, which are often overexpressed in cancer cells.
Active Substance: Afatinib is the active substance in Xovoltib. It belongs to the class of tyrosine kinase inhibitors, which work by inhibiting specific enzymes involved in cell signaling pathways that promote cancer cell growth and proliferation. By targeting the EGFR family of proteins, afatinib helps to block the signaling pathways that contribute to tumor growth and progression.
Form: Xovoltib is available in the form of tablets, with each tablet containing 20 mg of afatinib. The medication is typically supplied in blister packs containing 28 tablets, providing a standardized and convenient dosage regimen.
Xovoltib is manufactured by Bharat Serums and Vaccines Limited, a reputable pharmaceutical company known for its commitment to producing high-quality and innovative medications. Bharat Serums and Vaccines Limited adheres to stringent quality control measures and regulatory standards to ensure the safety, efficacy, and consistency of its products.
Xovoltib is commonly prescribed by healthcare providers for the treatment of patients with metastatic NSCLC or metastatic squamous cell carcinoma of the lung, particularly those with tumors that harbor certain EGFR mutations. It is usually taken orally once daily, with or without food. Dosage adjustments may be necessary based on individual patient factors and response to treatment. Regular monitoring and follow-up with a healthcare provider are essential for the management of potential side effects and assessment of treatment efficacy.
Reviews
There are no reviews yet.